Xelcisbio
Xelcis Bio develops next-generation targeted cancer therapeutics using its proprietary TRIDENT™ delivery platform. This technology integrates nanoparticle delivery with chemotherapy to precisely target tumors, aiming to increase efficacy while minimizing systemic toxicity. The company is leveraging the FDA 505(b)(2) pathway to accelerate the development and market entry of its enhanced drug delivery systems.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Xelcis Bio develops next-generation targeted cancer therapeutics using its proprietary TRIDENT™ delivery platform. This technology integrates nanoparticle delivery with chemotherapy to precisely target tumors, aiming to increase efficacy while minimizing systemic toxicity. The company is leveraging the FDA 505(b)(2) pathway to accelerate the development and market entry of its enhanced drug delivery systems.